Cladribine
Back to searchMolecule Structure
Scientific Name
Cladribine
Description of the Drug
Cladribine is a purine antimetabolite used for the management of relapsing forms of Multiple Sclerosis (MS), used in patients who have not responded to or who were unable to tolerate alternative MS drugs.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00242
http://www.drugbank.ca/drugs/DB00242
Brand Name(s)
Cladribine, Leustat, Leustatin, Litak, Mavenclad
Company Owner(s)
Fresenius Kabi Usa Llc, Mylan Laboratories Ltd, Hikma Pharmaceuticals Usa Inc, Hisun Pharmaceutical (Hangzhou) Co Ltd, Emd Serono Inc, Janssen Pharmaceuticals Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL3775 | |||
PharmGKB | PA449027 | |||
Human Metabolome Database | HMDB0014387 | |||
DrugBank | DB00242 | |||
PubChem: Thomson Pharma | 14897807 | 14799875 | ||
PubChem | 20279 | |||
LINCS | LSM-5976 | |||
Nikkaji | J446.344G | |||
PDBe | CL9 | |||
BindingDB | 38920 | |||
EPA CompTox Dashboard | DTXSID8022828 | |||
DrugCentral | 667 | |||
Brenda | 143941 | 2913 | 5796 | 8475 |
Guide to Pharmacology | 4799 | |||
rxnorm | MAVENCLAD | CLADRIBINE | ||
PubChem: Drugs of the Future | 99431527 | |||
ChEBI | 567361 | |||
ZINC | ZINC000003798064 |